Arovella Therapeutics Limited (ALA) Fair Value & Analysis
Healthcare · AU · Market cap A$83.4M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0700 to A$0.0356 (−49.1%) since Jun 24, 2026. Share price −8.3% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0650 – A$0.1150 · fair‑value band A$0.0290 – A$0.0356 · the A$0.0660 price screens above the A$0.0356 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Arovella Therapeutics Limited (ALA) currently trades at A$0.0660, while our model-based Fair Value estimate is A$0.0356 — implying the stock looks roughly 46.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$3.2M. Revenue declined 6.7% year over year. It earns a return on equity of -52.1%. The balance sheet holds a net cash position of A$20.9M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Arovella Therapeutics Limited reported revenue of A$136K in FY2025 versus A$257K in FY2021, a compound −14.7%/yr. Reported net income was −A$7.5M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $288.18 | $51.70 | -82% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Arovella Therapeutics Limited (ALA) undervalued?
What is the fair value of ALA?
What is the quality score of ALA?
What is the revenue of Arovella Therapeutics Limited (ALA)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.